Varian v. Einhorn: Memphis $38 Million and the Tennessee Cap Calculus
The largest Tennessee medical-malpractice verdict of 2026 came out of Shelby County in April, when a jury returned a $38 million award against physicians at Regional One Health in the case of Varian v. Einhorn. Plaintiff counsel Thomas Greer of Greer Injury Lawyers (Memphis) presented an 11-day trial record showing that physicians delayed a cesarean despite meconium-stained amniotic fluid, elevated white blood cell counts, and persistent fetal heart rate abnormalities.
The child required ECMO life support and spent 2.5 months hospitalized. A stroke at 10 months produced permanent intellectual and physical disabilities. The jury's $38 million response encompasses both economic and non-economic losses, but Tennessee's statutory caps will substantially shape any final judgment after post-trial motions.
Under Tennessee Code Annotated Section 29-39-102, non-economic damages in standard malpractice actions are capped at $750,000, with a $1 million ceiling reserved for cases meeting the catastrophic-injury classification. Whether the trial court certifies catastrophic status will determine how much of the verdict survives. Plaintiff counsel will also need to examine whether Regional One Health physicians were operating under a governmental entity framework that independently modifies the cap analysis under state sovereign immunity provisions.
Bar takeaway: Before filing a birth-injury case in Tennessee, separate economic damages (uncapped) from non-economic damages and determine on the trial record whether catastrophic-injury criteria under TCA Section 29-39-102 are pleadable, because that single classification decision controls several hundred thousand dollars of the recoverable non-economic award.
Philadelphia Birth-Injury Docket: $108.6 Million, Retrial Order, and the Spencer Hysterectomy Verdict
A Philadelphia Court of Common Pleas jury awarded $108.6 million on March 20, 2026, against Jefferson Health and its Einstein Pediatrics unit in a birth-injury action. The breakdown was precise: $106.1 million in projected future medical costs calculated over a 68-year lifespan, $1.4 million for pain and suffering, and $1 million in lost earnings. The trial judge subsequently vacated the award, finding that it 'did not make logical or legal sense,' and ordered a new trial.
The parties settled before the retrial date for an undisclosed sum, completing a sequence that mirrors what remains Pennsylvania's largest prior birth-injury resolution: a $183 million Penn Medicine verdict from three years earlier that also resolved confidentially following post-trial challenge. Philadelphia plaintiff counsel handling catastrophic birth-injury cases should treat retrial-order risk as a built-in litigation phase, not a contingency, and prepare structured-settlement modeling before trial to anchor future-medical projections against remittitur arguments.
On a separate Philadelphia docket, Isis Spencer v. Penn Medicine and Main Line Health produced a $35 million verdict in 2026. Spencer underwent a total hysterectomy that proved unnecessary after a false advanced endometrial cancer diagnosis. Lead counsel Glenn A. Ellis of the Law Offices of Glenn A. Ellis secured $12.25 million attributed to the Penn Medicine defendants on apportionment.
Bar takeaway: The Philadelphia retrial-then-settle pattern in catastrophic birth-injury matters is now documented across multiple cases; when future medical costs are projected over decades and exceed $100 million, anticipate a retrial motion and price that risk into settlement posture before the jury returns.
California MICRA Caps at January 2026: The $470,000 Non-Fatal Ceiling and Its Lien-Stage Consequences
California AB 35 (2022) embedded annual cap increases that activated January 1, 2026. Non-fatal medical-malpractice cases now carry a $470,000 non-economic damages ceiling, an increase of $40,000 from 2025. Wrongful death cases sit at $650,000. Both figures rise annually until reaching $750,000 and $1 million, respectively, by 2033.
The trajectory matters beyond the trial stage. Defense adjusters benchmark non-economic exposure against the statutory ceiling when evaluating total settlement value, and as that ceiling climbs $40,000 to $50,000 each January, settlement leverage for California med-mal plaintiffs improves in measurable increments. At the same time, the argument that a lien-position provider's billing is disproportionate to total case value becomes progressively harder to sustain as the cap rises toward the $750,000 floor.
Providers holding treatment liens in California cases should document billing under Howell v. Hamilton Meats standards contemporaneously. Courts reviewing reasonable value will consider whether charges align with regional fee schedules and CPT benchmarks, independent of where the MICRA non-economic ceiling sits in any given year.
Bar takeaway: California med-mal cases resolving in 2026 operate under a $470,000 non-economic cap for non-fatal claims; counsel and lien-position providers should calendar each January 1 adjustment, update demand packages accordingly, and maintain Howell-compliant billing documentation before any settlement stage.
FDA Q1 2026 Recall Data and GAO-26-107619: Product-Liability Case File Additions
Device failure ranked as the leading cause of FDA medical device recalls in the first quarter of 2026, generating 41 discrete recall events. Spinal cord stimulators drew the highest-profile attention: Class I recalls covering Abbott Proclaim and multiple Boston Scientific models were issued for MRI-mode therapy disruptions tied to 73 reported injuries, adding to a cumulative total exceeding 80,000 injury reports for the SCS device category since 2008.
GAO Report GAO-26-107619, released in 2026, assessed the FDA recall process and identified systemic limitations in how HHS and FDA coordinate post-market surveillance and recall follow-through. The report documented coordination gaps that leave the post-recall oversight loop materially incomplete.
For product-liability plaintiff counsel handling SCS device cases, GAO-26-107619 adds a second evidentiary layer beyond the recall notice. Establishing that FDA's own accountability function flagged structural oversight deficiencies supports failure-to-warn and inadequate-regulatory-response arguments and may carry weight in punitive damages theories where the device defendant had access to the same public record before the injury event.
Bar takeaway: In Abbott Proclaim and Boston Scientific SCS device-injury cases, GAO-26-107619's documented FDA oversight deficiencies are a public record that should be attached to the notice argument alongside the Class I recall filings, particularly in failure-to-warn and punitive damages counts.
Operations: Lien-Provider Billing Defensibility and the Telehealth Standard-of-Care Frontier
For medical providers holding California treatment liens, the MICRA cap increase adjusts total-case leverage but does not resolve the billing-reasonableness question courts apply on a separate track. Under the Howell v. Hamilton Meats line and the California Court of Appeal's subsequent decision in Corenbaum v. Lampkin, the recoverable amount for medical services is the reasonable value of care, not the face-value billed charge. Providers whose rates materially exceed regional market levels or Medicare benchmarks without documented clinical justification face lien compression regardless of where the statutory non-economic ceiling sits.
Two concrete steps reduce that exposure. First, maintain per-case billing reconciliation files that tie each charge to a prevailing regional rate source at the time of service. Second, specify in lien agreements with plaintiff counsel that final billing records will be produced in complete form before any settlement demand is transmitted to the defense side.
Telehealth entities face a distinct and less-settled liability exposure. Post-pandemic virtual-care platforms handling post-surgical follow-up, prescription management, and specialist referrals are appearing as defendants in misdiagnosis and medication-error cases in California and Florida. Neither state has published a unified telehealth standard-of-care framework. The question before multiple trial courts is whether a virtual-care provider's duty of care tracks the in-person clinical standard or accounts for the structural constraints of remote examination — a point that remains unresolved in published case law as of Q2 2026.
Bar takeaway: California lien-holding providers should audit billing files under Howell standards before any demand is issued; telehealth entities providing post-surgical or prescription-management services should document remote-exam protocols now, before California or Florida courts publish a controlling standard-of-care ruling that sets the benchmark retroactively.